RADAR试验:精神分裂症等复发性精神病性障碍的抗精神病药减量与维持治疗对照研究
RADAR是一项在英格兰19家NHS信托机构开展的非盲平行组随机试验,纳入253名复发性非情感性精神病性障碍患者,比较渐进灵活减量抗精神病药与维持治疗。减量组严重不良事件93例(涉及49人),维持组64例(涉及29人),主要为因精神疾病复发住院。
要点
- 渐进减量抗精神病药在2年随访时对社会功能无显著影响。
- 减量组严重不良事件数多于维持组,主要为精神疾病复发住院。
- 减量过程中位最大减量幅度为67%,24个月时减量组中位减量为33%。
核心结论
- 在2年随访时,渐进、有支持的抗精神病药减量对社会功能无影响。
- 研究数据可帮助指导长期抗精神病药使用的决策。
研究设计与样本
- RADAR为开放、平行组、随机对照试验,在英格兰19家National Health Service信托机构进行。
- 纳入18岁及以上、诊断为复发性非情感性精神病性障碍且正在服用抗精神病药的患者,共随机分配253人(减量组126人,维持组127人)。
- 参与者按1:1随机分配至渐进灵活减量组(由治疗临床医生监督)或维持组,随访2年,评估者设盲,采用意向性治疗分析。
主要发现
- 减量组试验期间任意时点中位减量为67%,维持组为零;24个月时分别为33%与零。
- 减量组发生93例严重不良事件(涉及49人),维持组64例(涉及29人),主要为因精神健康复发住院。
临床怎么用
- 对于病情稳定的复发性非情感性精神病性障碍患者,可在密切监测下考虑渐进减量抗精神病药,但需警惕复发住院风险。
- 减量决策应结合患者具体情况,权衡社会功能与复发风险,目前证据未显示减量改善社会功能。
局限性
- 开放设计,参与者和临床医生知晓分组,可能影响行为与报告。
- 24个月随访时评估率不高(减量组90/126,维持组94/127),可能存在 attrition 偏倚。
- 样本量较小(253人),可能不足以检测社会功能的微小差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Maintenance antipsychotic medication is recommended for people with schizophrenia or recurrent psychosis, but the adverse effects are burdensome, and evidence on long-term outcomes is sparse. We aimed to assess the benefits and harms of a gradual process of antipsychotic reduction compared with maintenance treatment. Our hypothesis was that antipsychotic reduction would improve social functioning with a short-term increase in relapse. METHODS: RADAR was an open, parallel-group, randomised trial done in 19 National Health Service Trusts in England. Participants were aged 18 years and older, had a diagnosis of recurrent, non-affective psychotic disorder, and were prescribed an antipsychotic. Exclusion criteria included people who had a mental health crisis or hospital admission in the past month, were considered to pose a serious risk to themselves or others by a treating clinician, or were mandated to take antipsychotic medication under the Mental Health Act. Through an independent, internet-based system, participants were randomly assigned (1:1) to gradual, flexible antipsychotic reduction, overseen by treating clinicians, or to maintenance. Participants and clinicians were aware of treatment allocations, but assessors were masked to them. Follow-up was for 2 years. Social functioning, assessed by the Social Functioning Scale, was the primary outcome. The principal secondary outcome was severe relapse, defined as requiring admission to hospital. Analysis was done blind to group identity using intention-to-treat data. The trial is completed and has been registered with ISRCTN registry (ISRCTN90298520) and with ClinicalTrials.gov (NCT03559426). FINDINGS: 4157 people were screened, of whom 253 were randomly allocated, including 168 (66%) men, 82 (32%) women, and 3 (1%) transgender people, with a mean age of 46 years (SD 12, range 22-79). 171 (67%) participants were White, 52 (21%) were Black, 16 (6%) were Asian, and 12 (5%) were of other ethnicity. The median dose reduction at any point during the trial was 67% in the reduction group and zero in the maintenance group; at 24 months it was 33% versus zero. At the 24-month follow-up, we assessed 90 of 126 people assigned to the antipsychotic dose reduction group and 94 of 127 assigned to the maintenance group, finding no difference in the Social Functioning Scale (β 0·19, 95% CI -1·94 to 2·33; p=0·86). There were 93 serious adverse events in the reduction group affecting 49 individuals, mainly comprising admission for a mental health relapse, and 64 in the maintenance group, relating to 29 individuals. INTERPRETATION: At 2-year follow-up, a gradual, supported process of antipsychotic dose reduction had no effect on social functioning. Our data can help to inform decisions about the use of long-term antipsychotic medication. FUNDING: National Institute for Health Research.
引用
- Moncrieff J, Crellin N, Stansfeld J, et al. Antipsychotic dose reduction and discontinuation versus maintenance treatment in people with schizophrenia and other recurrent psychotic disorders in England (the RADAR trial): an open, parallel-group, randomised controlled trial. Lancet Psychiatry. 2023. PMID: 37778356. doi:10.1016/S2215-0366(23)00258-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。